Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae

Antimicrob Agents Chemother. 2003 Oct;47(10):3343-4. doi: 10.1128/AAC.47.10.3343-3344.2003.

Abstract

The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage*
  • Amphotericin B / chemistry
  • Animals
  • Deoxycholic Acid / administration & dosage*
  • Diabetes Mellitus, Experimental / microbiology*
  • Drug Combinations
  • Humans
  • Liposomes
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mucormycosis / complications
  • Mucormycosis / drug therapy*
  • Rhizopus*

Substances

  • Drug Combinations
  • Liposomes
  • Deoxycholic Acid
  • Amphotericin B
  • amphotericin B, deoxycholate drug combination